Skip to main content
. 2023 Jul 11;14:1178489. doi: 10.3389/fphar.2023.1178489

FIGURE 5.

FIGURE 5

Collateral sensitivity was seen in irinotecan-resistant HT-29 cells. (A). Measurement of growth rate differences at 24 h intervals for irinotecan-resistant HT-29 replicate B. (B). Migratory abilities of irinotecan-resistant HT-29 replicate B and DMSO control HT-29 cell lines were measured based on the percentage of wound closure in 24h, 36h, 48h, and 72 h intervals. (C). Collateral sensitivity to dabrafenib was identified in irinotecan-resistant HT-29 replicate B. (D). Irinotecan and capecitabine combination exhibited collateral sensitivity in irinotecan-resistant HT-29 replicate B. (E). Loewe score showed additive effect of irinotecan and capecitabine combination in inducing collateral sensitivity. (F). Combination of irinotecan and dabrafenib demonstrated collateral sensitivity in irinotecan-resistant HT-29 replicate B. (G). Synergy testing using Loewe score showed additive effects for irinotecan and dabrafenib combination in inducing collateral sensitivity in irinotecan-resistant HT-29 replicate B. Error bars represent SEM. *p < 0.5, **p < 0.01, ***p < 0.001 ****p < 0.0001.